Corcept Therapeutics, Inc. (NASDAQ:CORT)

CAPS Rating: 4 out of 5

A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.

CORT News and Commentary

Caps

How do you think CORT will perform against the market?

Add Stock to CAPS Watchlist

All Players

87 Outperform
27 Underperform
 

All-Star Players

13 Outperform
5 Underperform
 

Wall Street

3 Outperform
1 Underperform
 

Top CORT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

vistacarolina (41.78)
Submitted March 31, 2017

Great Co. will see positive results.

zzlangerhans (99.82)
Submitted July 13, 2016

In medicine we generalists have a saying: When you only tool is a hammer, every problem becomes a nail. It refers to the propensity of specialists to interpret every problem through the lens of their specialty. If a patient comes in with syncope, the… More

CORT VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about CORT.

Recs

2
Member Avatar vistacarolina (41.78) Submitted: 3/31/2017 6:36:52 PM : Outperform Start Price: $11.00 CORT Score: +57.93

Great Co. will see positive results.

Recs

2
Member Avatar zzlangerhans (99.82) Submitted: 7/13/2016 9:38:18 AM : Underperform Start Price: $5.52 CORT Score: -208.72

In medicine we generalists have a saying: When you only tool is a hammer, every problem becomes a nail. It refers to the propensity of specialists to interpret every problem through the lens of their specialty. If a patient comes in with syncope, the cardiologist wants to order an ECHO and the neurologist wants an MRI. In the case of Corcept, their only tool is mifepristone and they generate pipeline by finding new diseases to apply their tool against. The Cushing's syndrome indication likely won't be enough to turn Corcept cash-flow positive, so the company has turned its attention to cancers, specifically TNBC and CRPC. There's some independent evidence that this may be an effective strategy, but not much. As of now I think Corcept is overvalued at a cap of 600M for Korlym's weak revenues and risky prospects as a cancer drug.

Recs

0
Member Avatar g60 (72.41) Submitted: 2/25/2014 3:48:43 PM : Outperform Start Price: $3.39 CORT Score: +401.15

Armando

Leaderboard

Find the members with the highest scoring picks in CORT.

Score Leader

thiscoloradokid

thiscoloradokid (< 20) Score: +1,022.58

The Score Leader is the player with the highest score across all their picks in CORT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
thiscoloradokid < 20 12/5/2012 12/4/2013 Outperform 3M $1.52 +1,103.29% +80.71% +1,022.58 0 Comment
alvojiggy 81.02 10/23/2013 Outperform 5Y $1.73 +957.23% +46.14% +911.08 0 Comment
GOGCwatch07 < 20 9/18/2013 Outperform 5Y $1.73 +957.23% +49.39% +907.84 0 Comment
duff5569 45.38 5/8/2014 Outperform 5Y $1.97 +828.43% +36.13% +792.30 0 Comment
wgrohman < 20 3/21/2013 Outperform 3Y $1.94 +842.78% +65.07% +777.71 0 Comment
FinanceGuy58 71.72 12/9/2013 7/24/2015 Outperform 3Y $2.01 +812.22% +40.94% +771.28 0 Comment
loangolfer < 20 1/10/2013 Outperform 5Y $1.96 +832.69% +74.22% +758.47 0 Comment
HoldThatWinner 30.42 3/11/2013 Outperform 1Y $2.00 +814.50% +64.47% +750.03 0 Comment
HoosierDoozer 41.52 12/5/2013 Outperform 5Y $2.06 +787.86% +42.39% +745.47 0 Comment
rserafini 72.22 3/25/2013 Outperform 5Y $2.04 +796.57% +63.75% +732.82 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackPiperJaff 87.02 3/11/2015 Outperform NS $3.95 +363.04% +24.44% +338.59 0 Comment
TrackCreditSuiss 90.46 11/13/2012 Outperform NS $1.35 +25.93% +23.19% +2.74 8/9/2013 @ $1.70 0 Comment
TrackJMP 82.93 2/21/2012 Outperform NS $4.60 +297.61% +86.71% +210.90 0 Comment
TrackBioLogicEqu < 20 1/5/2012 Underperform NS $3.38 +441.12% +101.14% -339.98 0 Comment
TrackLadenburg < 20 1/6/2010 Outperform NS $2.99 +511.71% +125.04% +386.66 0 Comment
TrackTWeisel 85.81 8/15/2006 Outperform NS $3.69 -100.00% +1.93% -101.93 8/25/2006 @ $0.00 0 Comment

Featured Broker Partners